Therapy Areas: AIDS & HIV
Inimmune signs research collaboration with Boston Children's Hospital
25 October 2023 -

Inimmune Corporation, a US-based clinical-stage biotechnology company, announced on Tuesday that it has signed a research collaboration with Boston Children's Hospital (BCH).

The research collaboration is aimed at developing novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer-lasting immunity against infections than the vaccine alone.

The Precision Vaccines Program (PVP) at Boston Children's Hospital was awarded a Vaccine Adjuvant Development Program contract (75N93023C00040) from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) that can extend up to five years and USD9m to develop a small molecule TLR7/8 agonist adjuvant that will enhance the effectiveness of flu vaccines.

Ofer Levy, MD, PhD, director of the PVP, said: "The Precision Vaccines Program is dedicated to pioneering the next generation of vaccines tailored to safeguard the most vulnerable among us. We are building a global network to revolutionise vaccine development, and we are excited to collaborate with Inimmune to enhance adjuvants."